OPK•OPKO Health said third-quarter revenue rose year over year and its operating loss narrowed to $31.4 million. It expects fourth-quarter revenue of $62 million to $72 million and 2026 revenue of $268 million to $278 million.
OPKO Health’s third-quarter revenue rose year over year, while its operating loss narrowed to $31.4 million. The company expects fourth-quarter revenue of $62 million to $72 million and 2026 full-year revenue of $268 million to $278 million.
Higher royalty revenue from Lilly, increased Rayaldee sales and growth in international operations drove revenue gains. Rayaldee sales also benefited from favorable gross-to-net adjustments related to Medicare coverage changes. OPKO withdrew its guidance for services revenue and total costs because of the pending Labcorp transaction.
